Flow cytometry analysis revealed that the frequency of Epas1-Crispr-treated OT-I T cells in tumor-infiltrating lymphocytes was significantly lower than in controls (Figures 7C, D, Supplementary Figure S5A). Here, EPAS1 is linked to neoplasm.